Načítá se...
Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
PURPOSE: The purpose of our study is to report our experience with the use of certolizumab pegol in patients with refractory non-infectious uveitis. OBSERVATIONS: We present a case series of three patients with non-infectious uveitis, treated with twice-monthly subcutaneous certolizumab pegol. All o...
Uloženo v:
| Vydáno v: | Am J Ophthalmol Case Rep |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7068621/ https://ncbi.nlm.nih.gov/pubmed/32190782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2020.100633 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|